11-(2-PYRROLIDIN-1-YL-ETHOXY)-14,19-DIOXA-5,7,26-TRIAZA-TETRACYCLO[19.3.1.1(2,6).1(8,12)]HEPTACOSA-1(25),2(26),3,5,8,10,12(27),16,21,23-DECAENE CITRATE SALT
    1.
    发明申请
    11-(2-PYRROLIDIN-1-YL-ETHOXY)-14,19-DIOXA-5,7,26-TRIAZA-TETRACYCLO[19.3.1.1(2,6).1(8,12)]HEPTACOSA-1(25),2(26),3,5,8,10,12(27),16,21,23-DECAENE CITRATE SALT 有权
    11-(2-吡咯烷-1-基 - 乙氧基)-14,19-二氧杂环己烯-5,7,26-三唑并[3,4-b] [19.3.1.1(2,6).1(8,12)] HEPTACOSA-1( 25),2(26),3,5,8,10,12(27),16,21,23 - 十六烷基硫酸盐

    公开(公告)号:US20110294831A1

    公开(公告)日:2011-12-01

    申请号:US13133297

    申请日:2009-12-09

    Abstract: The present invention relates to certain salts of a 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (Compound I) which have been found to have improved properties. In particular the present invention relates to the citrate salt of this compound. The invention also relates to pharmaceutical compositions containing the citrate salt and methods of use of the citrate salt in the treatment of certain medical conditions.

    Abstract translation: 本发明涉及11-(2-吡咯烷-1-基 - 乙氧基)-14,19-二氧杂-5,7,26-三氮杂 - 四环[19.3.1.1(2,6).1( 8,12)],已被发现具有改善的性能的十七酸-1(25),2(26),3,5,8,10,12(27),16,21,23-十氢烯(化合物I)。 特别地,本发明涉及该化合物的柠檬酸盐。 本发明还涉及含有柠檬酸盐的药物组合物和柠檬酸盐在使用某些医疗条件下的使用方法。

    11-(2-PYRROLIDIN-1-YL-ETHOXY)-14,19-DIOXA-5,7,26-TRIAZA-TETRACYCLO[19.3.1.1(2,6).1(8,12)]HEPTACOSA-1(25),2(26),3,5,8,10,12(27),16,21,23-DECAENE CITRATE SALT
    5.
    发明申请
    11-(2-PYRROLIDIN-1-YL-ETHOXY)-14,19-DIOXA-5,7,26-TRIAZA-TETRACYCLO[19.3.1.1(2,6).1(8,12)]HEPTACOSA-1(25),2(26),3,5,8,10,12(27),16,21,23-DECAENE CITRATE SALT 审中-公开
    11-(2-吡咯烷-1-基 - 乙氧基)-14,19-二氧杂环己烯-5,7,26-三唑并[3,4-b] [19.3.1.1(2,6).1(8,12)] HEPTACOSA-1( 25),2(26),3,5,8,10,12(27),16,21,23 - 十六烷基硫酸盐

    公开(公告)号:US20150322084A1

    公开(公告)日:2015-11-12

    申请号:US14621726

    申请日:2015-02-13

    Abstract: The present invention relates to certain salts of a 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (Compound I) which have been found to have improved properties. In particular the present invention relates to the citrate salt of this compound. The invention also relates to pharmaceutical compositions containing the citrate salt and methods of use of the citrate salt in the treatment of certain medical conditions.

    Abstract translation: 本发明涉及11-(2-吡咯烷-1-基 - 乙氧基)-14,19-二氧杂-5,7,26-三氮杂 - 四环[19.3.1.1(2,6).1( 8,12)],已被发现具有改善的性能的十七酸-1(25),2(26),3,5,8,10,12(27),16,21,23-十氢烯(化合物I)。 特别地,本发明涉及该化合物的柠檬酸盐。 本发明还涉及含有柠檬酸盐的药物组合物和柠檬酸盐在使用某些医疗条件下的使用方法。

    Method for production of hydroxylamine sulfate in the conventional process for the synthesis of caprolactam
    6.
    发明授权
    Method for production of hydroxylamine sulfate in the conventional process for the synthesis of caprolactam 有权
    用于合成己内酰胺的常规方法生产硫酸羟胺的方法

    公开(公告)号:US06469163B1

    公开(公告)日:2002-10-22

    申请号:US09221209

    申请日:1998-12-24

    CPC classification number: C07D201/06 C07D201/10

    Abstract: An improvement in the conventional process for the production of caprolactam. The process involves: (a) reacting air with ammonia gas in an ammonia conversion zone to produce nitric oxide; (b) oxidizing a portion of the nitric oxide to nitrogen dioxide to produce an NOx-rich process gas stream; (c) reacting the NOx-rich stream with ammonium carbonate in a nitriting zone to produce ammonium nitrite; (d) reducing the ammonium nitrite to hydroxylamine diammonium sulfate; (e) hydrolyzing the hydroxylamine diammonium sulfate to hydroxylamine sulfate; (f) oximating the hydroxylamine sulfate with cyclohexanone to produce cyclohexanone oxime; and (g) converting the cyclohexanone oxime to caprolactam. The process is improved by adding supplemental oxygen downstream of the ammonia conversion zone to increase the quantity and rate of formation of nitrogen dioxide in the NOx-rich process gas stream.

    Abstract translation: 制备己内酰胺的常规方法的改进。 该方法包括:(a)在氨转化区中使空气与氨气反应以产生一氧化氮;(b)将一部分氧化氮氧化成二氧化氮以产生富含NO x的工艺气流;(c)使 在氮化区中用碳酸铵生成富含NO x的物流以产生亚硝酸铵;(d)将亚硝酸铵还原为羟胺二硫酸铵;(e)将羟胺二硫酸铵水解成硫酸羟胺;(f)用环己酮将硫酸羟胺酸化 生产环己酮肟; 并且(g)将环己酮肟转化为己内酰胺。通过在氨转化区下游加入补充氧以提高富氮过程气流中二氧化氮形成的数量和速率,从而提高了工艺。

Patent Agency Ranking